Pain Therapeutics Logo

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase
« Previous Release | Next Release »

Pain Therapeutics Reports Q3 2013 Financial Results

AUSTIN, Texas, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the quarter and nine months ended September 30, 2013. Net loss was $762,000, or $0.02 per share in Q3 2013, compared to a net loss of $1,550,000, or $0.03 per share in Q3 2012. Cash and investments were $51.0 million at September 30, 2013.

"We still expect our net cash usage to be under $10 million in CY2013," said Remi Barbier, Chairman, President & CEO. "Based on recent developments, we also believe Pfizer has a robust plan to resubmit the REMOXY® NDA. Key elements of this plan include doing a bioequivalence study and an abuse-potential study using REMOXY, all of which we believe may result in a stream of technical milestones now through 2015."

Q3 2013 Financial Detail


Our lead drug candidate, REMOXY, is an extended-release oral formulation of oxycodone for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. We designed REMOXY to discourage common methods of tampering and misuse.

Pfizer, Inc. (NYSE:PFE) is our exclusive, worldwide commercial partner for REMOXY® (oxycodone) Extended-Release Capsules CII, except as to Australia and New Zealand.

REMOXY Deal Economics

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel drugs. The FDA has not approved any of our drug candidates for commercial sale. For more information, please visit

Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the company's projected cash usage for 2013; Pfizer's development plan, including expected studies, and the timing of any complete response submission for REMOXY; potential future milestone payments and royalties under the strategic alliance with Pfizer based on milestones and on revenue from REMOXY; the potential development of other abuse-resistant drug candidates; and funding obligations of Pfizer under the strategic alliance. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in carrying out additional studies relating to, and obtaining regulatory approval of REMOXY and in development, testing and pursuit of regulatory approval of our other drug candidates; unexpected adverse side effects or inadequate therapeutic efficacy of our drug candidates; possible decisions by Pfizer to delay or not continue, or to devote less resources to, the development of REMOXY; difficulties or delays in commercialization efforts with respect to our products, if any are approved for marketing, or failure of such products to gain market acceptance; the uncertainty of patent protection for our intellectual property or trade secrets; unanticipated additional research and development, litigation and other costs; and the potential for abuse-resistant pain medications or other competing products or therapies to be developed by competitors and potential competitors or others. For further information regarding these and other risks related to the Company's business, investors should consult the Company's filings with the Securities and Exchange Commission.

— Financial Tables Follow —

(in thousands, except per share amounts)
  Three Months Ended September 30, Nine Months Ended September 30,
  2013 2012 2013 2012
 Program fee revenue   $ 1,958  $ 2,725  $ 5,875  $ 8,173
 Collaboration revenue   --  --  --  249
 Total revenue   1,958  2,725  5,875  8,422
 Operating expenses         
 Research and development   1,444  2,379  3,766  5,504
 General and administrative   1,290  2,001  3,647  4,975
 Total operating expenses   2,734  4,380  7,413  10,479
 Operating loss   (776)  (1,655)  (1,538)  (2,057)
 Interest income   14  105  67  405
 Net loss   $ (762)  $ (1,550)  $ (1,471)  $ (1,652)
Net loss per share, basic and diluted  $ (0.02)  $ (0.03)  $ (0.03)  $ (0.04)
Weighted-average shares used in computing net loss per share, basic and diluted  45,037  44,601  44,990  44,703
(in thousands)
      September 30,
December 31,
 Current assets         
 Cash, cash equivalents and marketable securities       $ 51,027  $ 56,254
 Other current assets       389  253
 Total current assets       51,416  56,507
 Non-current assets         
 Other assets       340  352
 Total assets       $ 51,756  $ 56,859
 Liabilities and stockholders' equity         
 Current liabilities         
 Accounts payable and accrued development expenses     $ 1,273  $ 1,290
 Deferred program fee revenue - current portion       7,832  7,832
 Other accrued liabilities       550  877
 Total current liabilities       9,655  9,999
 Non-current liabilities         
 Deferred program fee revenue - non-current portion     27,412  33,287
 Other liabilities       437  437
 Total liabilities       37,504  43,723
 Stockholders' equity         
 Common Stock and additional paid-in-capital       151,373  148,783
 Accumulated other comprehensive income       1  4
 Accumulated deficit       (137,122)  (135,651)
 Total stockholders' equity       14,252  13,136
 Total liabilities and stockholders' equity       $ 51,756  $ 56,859
(1) Derived from the Company's annual financial statements as of December 31, 2012, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission.
CONTACT: For More Information Contact:


         Peter S. Roddy

         Vice President and Chief Financial Officer

         Pain Therapeutics, Inc.

         (512) 501-2450

Close window | Back to top